DelveInsight’s, “Psoriatic Arthritis Pipeline Insight” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape. It covers the Psoriatic Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriatic Arthritis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Psoriatic Arthritis Treatment Landscape. Click here to read more @ Psoriatic Arthritis Pipeline Outlook
Key Takeaways from the Psoriatic Arthritis Pipeline Report
- In January 2025:- UCB Biopharma SRL:- A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis. The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
- In January 2025:- Janssen Pharmaceuticals:- The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapies by assessing clinical response compared with guselkumab monotherapy.
- In January 2025:- Eli Lilly and Company:- The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab.
- DelveInsight’s Psoriatic Arthritis pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Psoriatic Arthritis treatment.
- The leading Psoriatic Arthritis Companies such as Pfizer, selectION Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi, Inc., Hansoh BioMedical R&D Company, Bio-Thera Solutions, Mylan Inc., ACELYRIN Inc. and others.
- Promising Psoriatic Arthritis Therapies such as NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, and others.
Discover groundbreaking developments in Psoriatic Arthritis therapies! Gain in-depth knowledge of key Psoriatic Arthritis clinical trials, emerging drugs, and market opportunities @ Psoriatic Arthritis Clinical Trials Assessment
Psoriatic Arthritis Emerging Drugs Profile
- Sotyktu: Bristol Myers Squibb
Sotyktu (deucravacitinib) is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action, representing a new class of small molecules. It is the first selective TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Bristol Myers Squibb scientists designed Sotyktu to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-23, IL-12 and Type 1 interferons (IFN), key cytokines involved in the pathogenesis of multiple immune-mediated diseases. Sotyktu achieves a high degree of selectivity by binding to the regulatory domain of TYK2, resulting in allosteric inhibition of TYK2 and its downstream functions. Sotyktu selectively inhibits TYK2 at physiologically relevant concentrations. At therapeutic doses, Sotyktu does not inhibit JAK1, JAK2 or JAK3. Currently, the drug is in the Phase III stage of its development for the treatment of Psoriasis Arthritis.
- HS-10374: Hansoh BioMedical R&D Company
HS-10374 mechanism of action is to inhibit (TYK2) that is tyrosine-kinase 2. TYK2 inhibitors work by blocking the TYK2 protein and the cellular signals that run through it. Those signals can in turn activate other immune proteins and are associated with inflammation. Its route of administration is orally. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Psoriasis Arthritis.
- si-544: selection
si-544, the Company´s lead candidate, selectively blocks Kv1.3, a key ion channel expressed disease-associated effector memory T (TEM) cells. Kv1.3 is essential for the chronic activation and proliferation of these cells which escape the control of the immune system and become malignant. TEM cells drive inflammation in many autoimmune diseases, including atopic dermatitis, psoriasis, rheumatoid arthritis, and multiple sclerosis. Currently, the drug is in the Phase I stage of its development for the treatment of Psoriasis Arthritis.
Stay informed about the Psoriatic Arthritis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Psoriatic Arthritis Unmet Needs
Psoriatic Arthritis Companies
Pfizer, selectION Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi, Inc., Hansoh BioMedical R&D Company, Bio-Thera Solutions, Mylan Inc., ACELYRIN Inc. and others.
Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Intramuscular
- Topical.
Psoriatic Arthritis Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Transform your understanding of the Psoriatic Arthritis Pipeline! See the latest progress in drug development and clinical research @ Psoriatic Arthritis Market Drivers and Barriers, and Future Perspectives
Scope of the Psoriatic Arthritis Pipeline Report
- Coverage- Global
- Psoriatic Arthritis Companies- Pfizer, selectION Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi, Inc., Hansoh BioMedical R&D Company, Bio-Thera Solutions, Mylan Inc., ACELYRIN Inc. and others.
- Psoriatic Arthritis Therapies- NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, and others.
- Psoriatic Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Psoriatic Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Immunological and Autoimmune Disorders Research–Access the Full Psoriatic Arthritis Pipeline Analysis Today! @ Psoriatic Arthritis Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Psoriatic Arthritis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Psoriatic Arthritis – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Sotyktu: Bristol Myers Squibb
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- HS-10374: Hansoh BioMedical R&D Company
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- si-544: selection
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Psoriatic Arthritis Key Companies
- Psoriatic Arthritis Key Products
- Psoriatic Arthritis – Unmet Needs
- Psoriatic Arthritis – Market Drivers and Barriers
- Psoriatic Arthritis – Future Perspectives and Conclusion
- Psoriatic Arthritis Analyst Views
- Psoriatic Arthritis Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/penile-implants-market